Skip to main content

Table 4 Comparative analysis of the associations between PCT, hsCRP and incident mortality

From: Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study

Subjects

Outcome

PCT

hsCRP

HR (95% CI)a

P

HR (95% CI)a

P

All subjects

All-cause mortality

1.15 (1.04 to 1.26)

0.006**

1.08 (0.98 to 1.19)

0.100

Cancer mortality

1.23 (1.06 to 1.41)

0.005**

1.02 (0.89 to 1.16)

0.788

CVD mortality

1.08 (0.89 to 1.30)

0.425

1.24 (1.03 to 1.49)

0.025*

Mortality from causes other than cancer and CVD

1.15 (0.95 to 1.39)

0.161

1.07 (0.89 to 1.28)

0.483

Men

All-cause mortality

1.13 (1.00 to 1.27)

0.047*

1.09 (0.97 to 1.23)

0.156

Cancer mortality

1.29 (1.08 to 1.54)

0.006**

0.96 (0.80 to 1.14)

0.632

CVD mortality

1.04 (0.83 to 1.30)

0.741

1.30 (1.01 to 1.66)

0.037*

Mortality from causes other than cancer and CVD

1.07 (0.86 to 1.34)

0.556

1.16 (0.92 to 1.47)

0.220

Women

All-cause mortality

1.13 (0.97 to 1.32)

0.106

1.07 (0.92 to 1.24)

0.362

Cancer mortality

1.09 (0.88 to 1.35)

0.430

1.13 (0.92 to 1.38)

0.261

CVD mortality

1.19 (0.87 to 1.62)

0.286

1.13 (0.84 to 1.51)

0.433

Mortality from causes other than cancer and CVD

1.21 (0.87 to 1.67)

0.251

0.92 (0.68 to 1.23)

0.568

  1. Cox regression analysis adjusted for age, sex, hypertension, diabetes, LDL, HDL, TG, renal function, BMI and smoking. aThe HR values are expressed as mean HR per quartile of the respective biomarker. BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; HR, hazard ratio; hsCRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; PCT, procalcitonin; TG, triglycerides. *P <0.05, **P <0.01.